Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

364 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.
George DJ, Ramaswamy K, Yang H, Liu Q, Zhang A, Greatsinger A, Ivanova J, Thompson B, Emir B, Hong A, Freedland SJ. George DJ, et al. Among authors: ramaswamy k. Prostate Cancer Prostatic Dis. 2024 Mar 27. doi: 10.1038/s41391-024-00816-0. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38538879
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.
Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Martini JF, Ramaswamy K, Casey M, Staehler M, Patard JJ; S-TRAC Investigators. Ravaud A, et al. Among authors: ramaswamy k. N Engl J Med. 2016 Dec 8;375(23):2246-2254. doi: 10.1056/NEJMoa1611406. Epub 2016 Oct 9. N Engl J Med. 2016. PMID: 27718781 Free article. Clinical Trial.
Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial.
Staehler M, Motzer RJ, George DJ, Pandha HS, Donskov F, Escudier B, Pantuck AJ, Patel A, DeAnnuntis L, Bhattacharyya H, Ramaswamy K, Zanotti G, Lin X, Lechuga M, Serfass L, Paty J, Ravaud A. Staehler M, et al. Among authors: ramaswamy k. Ann Oncol. 2018 Oct 1;29(10):2098-2104. doi: 10.1093/annonc/mdy329. Ann Oncol. 2018. PMID: 30412222 Free PMC article. Clinical Trial.
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.
Tagawa ST, Ramaswamy K, Huang A, Mardekian J, Schultz NM, Wang L, Sandin R, Lechpammer S, George DJ. Tagawa ST, et al. Among authors: ramaswamy k. Prostate Cancer Prostatic Dis. 2021 Dec;24(4):1032-1040. doi: 10.1038/s41391-021-00318-3. Epub 2021 Feb 21. Prostate Cancer Prostatic Dis. 2021. PMID: 33612825 Free PMC article.
Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials.
Tombal BF, Freedland SJ, Armstrong AJ, Beer TM, Stenzl A, Sternberg CN, Hussain M, Ganguli A, Ramaswamy K, Bhadauria H, Ivanescu C, Turnbull J, Holmstrom S, Saad F. Tombal BF, et al. Among authors: ramaswamy k. Prostate Cancer Prostatic Dis. 2022 Feb;25(2):288-295. doi: 10.1038/s41391-021-00447-9. Epub 2021 Sep 13. Prostate Cancer Prostatic Dis. 2022. PMID: 34518652 Free PMC article.
364 results